Conversion of azathioprine to mycophenolate mofetil and chronic graft failure progression

Area of Science:

• Nephrology
• Transplantation Immunology
• Pharmacology

Background:

• Chronic allograft nephropathy (CAN) is a major cause of long-term renal transplant failure.
• Immunosuppressive therapy is crucial for preventing rejection but can contribute to graft dysfunction.
• Optimizing immunosuppression in CAN patients is essential for improving graft survival.

Purpose of the Study:

• To assess the impact of switching immunosuppression from azathioprine (AZA) to mycophenolate mofetil (MMF) on renal graft function in patients with established CAN.
• To compare graft function and proteinuria changes over a 12-month period following the conversion.

Main Methods:

• A prospective study involving 35 renal transplant recipients diagnosed with CAN.
• Randomized patients into two groups: one group switched from AZA to MMF, while the control group continued their existing regimen (AZA, cyclosporine, prednisone).
• Graft function was monitored monthly via creatinine clearance (CCr) and proteinuria measurements for 12 months pre- and post-conversion.

Main Results:

• No significant differences in mean creatinine clearance or proteinuria were observed between the MMF conversion group and the control group.
• Graft function showed a parallel decline in both groups, indicating no benefit from the AZA to MMF switch.
• Pathohistological analysis confirmed advanced CAN in most patients, with morphological changes correlating negatively with graft function.

Conclusions:

• Conversion from azathioprine to mycophenolate mofetil is safe in renal transplant recipients with chronic allograft nephropathy.
• This specific immunosuppressive switch does not demonstrate significant benefits in halting or slowing graft function deterioration over a one-year period.
• Further research may be needed to explore alternative strategies for managing advanced CAN and improving long-term graft survival.